OBJECTIVE: To measure the effects of phentermine, an appetite supressant, on the release of brain dopamine (DA) and serotonin (5-HT) into striatal dialysates of freely moving rats. DESIGN: Microdialysis and high performance liquid chromatography. SUBJECTS: Unanesthetized rats. MEASUREMENTS: Samples collected every 20 min were assayed for both neurotransmitters in a single run, using high performance liquid chromatography with electrochemical detection. RESULTS: Baseline levels of DA and 5-HT in dialysates were 56 AE 16 and 3 AE 0.6 fmol/20 ml, respectively. Administration of phentermine (2 or 5 mg/kg) increased dialysate DA concentrations to 147 AE 17% (P`0.01) and 320 AE 89% (P`0.01) of baseline, respectively, without signi®cantly affecting 5-HT concentrations. Pretreatment with tetrodotoxin (TTX, 60 min, 1 mM), which abolished the basal release of DA and 5-HT into striatal dialysates, diminished the increase in DA concentrations induced by phentermine, but did not completely block it. Phentermine (2 or 5 mg/kg, i.p.) still stimulated DA release to 27 AE 13%and 85 AE 15%of baseline, respectively, in the presence of TTX. CONCLUSION: Phentermine increases brain DA but not 5-HT release in freely moving rats, and TTX reduces, but does not fully block this effect. This pattern is similar to that known to be produced by d-amphetamine.
Introduction
The anorectic drug phentermine, introduced into the USA in the 1970's, was thought to act, like its analog d-amphetamine, as a`sympathomimetic agent with stimulant properties' probably mediated by the catecholamines, i.e. noradrenaline. 1 That phentermine's action might also involve dopamine (DA) was suggested the ®nding that its anorectic activity could be blocked by pimozide, a DA receptor antagonist, 2 or by pretreatment with 6-hydroxydopamine, a toxin which damages both noradrenaline and DA brain neurons. 3 However, no direct evidence is available, even now, that phentermine increases intrasynaptic DA levels or enhances DA-mediated neurotransmission. An effect on catecholamine release presumably mediates both the anorectic effect and the numerous side-effects of the structurally-related drug d-amphetamine, 1,4,5 but not of dexfen¯uramine, which directly releases serotonin (5-HT) but not DA.
In 1984, Weintraub and associates 6 combined phentermine with another antiobesity drug, fen¯uramine, in the hope of reducing side effects observed when each compound was given separately. They found that the stimulant effects of phentermine and the sedative action of fen¯uramine were, in fact, diminished when the drugs were given in combination. 67 Fen¯uramine is, in fact, two chemicals, i.e. the dextro isomer, which enhances 5-HT-mediated neurotransmission by blocking 5-HT re-uptake 8 and, through its metabolite dexnorfen¯uramine, enhancing 5-HT release and activating 5-HT receptors, 9 and l-fen¯uramine, which acts like haloperidol, a DA receptor antagonist. 10 Hence combining phentermine with the l-fen¯uramine component of fen¯uramine might be expected to neutralize the pro-and antidopaminergic activities of the two drugs, if indeed phentermine is a dopaminergic compound.
We now show that phentermine administration to intact, awake rats increases brain DA release. This effect is shared with d-amphetamine, but not with dexfen¯uramine.
Experimental procedures

Animals
Male Sprague Dawley rats weighing 200±300 g were purchased from Taconic Farms (Germantown, NY); housed two per cage; kept on a 12:12 hr lightadark cycle; and given ad libitum access to food and water.
Drug treatments
Phentermine, dissolved in saline, was administered intraperitoneally. Tetrodotoxin (TTX) was dissolved in arti®cial cerebrospinal¯uid (ACSF). All pharmacological treatments were performed after stabilization of DA and 5-HT levels in perfusate, usually after about 90 min of perfusion. TTX (1 mM) was added to perfusates 60 min before animals received phentermine (1, 2 or 5 mg/kg, i.p.). Control animals received only the saline vehicle i.p., or the ACSF perfusate.
Brain microdialysis
Dialysis probes of a concentric design 11 were constructed from fused silica capillary tubing (Polymicro Technologies, Phoenix, AZ). Tubing of 140 mm diameter was inserted within wider silica capillary tubing (300 mm) and secured at the in¯ow site using epoxy resin. A 4 mm length of hollow microdialysis ®ber (Spectrum Medical Industries, CA) was sealed at its tip and secured between the end of the wider silica capillary tubing and the inner tubing, using a cyanoacrylate adhesive. As anticipated from the literature and from prior studies in our laboratory, the probes exhibited in vitro recoveries of 11 AE 2% and 15 AE 2% for DA and 5-HT; data were not corrected for probe recovery. Probes were implanted into the striatum (A, 0.7; L, 0.3; V, 76.5; with respect to bregma 12 ) of rats that had been anesthetized with ketamineaxylazine (87/13%; 1 mlakg, i.p.). Animals were used two days after surgery. The probes were perfused at a¯ow rate of 1.5 mlamin, using a CMA microperfusion pump (Carnegie Medicin, Acton, MA), with ACSF (in millimolar): Na 
HPLC with electrochemical detection
Dialysate samples were analyzed by reversed-phase HPLC coupled with electrochemical detection. The mobile phase was composed of 75 mM sodium dihydrogen phosphate (NaH2PO4), 1 mM sodium dodecyl sulfate (SDS), 0.1 mM ethylenediamine-tetraacetic acid (EDTA), 15% acetonitrile and 20% methanol; this was adjusted to pH 5.7 with sodium hydroxide. This mobile phase was delivered at a¯ow rate of 1 ml/ min (LC-10AD pump, Shimadzu, Columbia, MD) through an HR-80 column (C18, 4.6 6 80 mm, 3 mm, ESA, Bedford, MA). DA and 5-HT were detected using a coulometric detector (Coulochem II, ESA) coupled to a dual electrode analytical cell (model 5014). The potential of the ®rst electrode was set at 7175 mV, and that of the second at 175 mV. Under these conditions, the sensitivities for DA and 5-HT were 2 fmola20 ml.
Statistical analysis
The DA and 5-HT contents of each dialysate sample were expressed as a percent of baseline. Data represent means AE s.e.m. Effects of the different treatments were analyzed by one way analysis of variance (ANOVA). When signi®cant effects were found, post hoc between comparisons were carried out with Dunnett's test.
Reagents
The reagents used were phentermine and TTX (Sigma Chemical Co. MO, USA); NaH 2 PO 4 , SDS and EDTA (Fluka, Buchs, Switzerland); methanol, acetonitrile (EM Science, Cherry Hill, NJ, USA). Other reagents used were of the highest grade commercially available.
Results
Effect of a single dose of phentermine on DA and 5-HT levels in dialysates Baseline DA and 5-HT levels in striatal dialysates collected prior to drug administration were 56 AE 16 and 3 AE 0.6 fmola20 ml (n 25). A one mgakg phentemine did not affect dialysate DA or 5-HT levels (data not shown). Higher doses (2 or 5 mgakg) signi®cantly increased DA levels, but not those of 5-HT (Figure 1a and b) . The maximum increases were 148 AE 17 (P`0.01) and 320 AE 89% of baseline (P`0.01), respectively ( Figure 1a) . The increase in DA levels reached statistical signi®cance in the 20± 40 min sample at 2 mgakg, and in the 0±20 min sample at 5 mgakg. DA returned to baseline levels in 2 h.
Effect of TTX on the increases in DA levels induced by phentermine
To determine whether phentermine releases DA by a mechanism similar to that of amphetamine, a related compound, we examined the effect of the sodium channel blocker TTX, administered through the dialysis probe 60 min before phentermine administration and continuously thereafter. We and others had previously shown that tetrodotoxin does not completely block amphetamine-induced DA release, 13, 14 implying that at least part of the amphetamine's effect is via a carrier-mediated mechanism.
TTX diminished the increase in DA concentrations induced by phentermine, but did not completely block this increase. TTX given alone, reduced baseline DA ( Figure 2 ) and 5-HT (data not shown) release to unmeasurable levels. Administration of phentermine, 60 min after starting local application of TTX, still signi®cantly stimulated DA release into the dialysates (Figure 2) . Maximum release in the presence of TTX was to 27 AE 13% and 85 AE 15% of baseline levels, respectively, at the 2 or 5 mgakg phentermine doses.
These increases correspond to 6 AE 1 (P`0.01) and 39 AE 15 fmola20 ml (P`0.01), respectively.
Discussion
These data show that phentermine increases DA release in rat striatum without signi®cantly affecting that of 5-HT at the doses tested. A related antiobesity drug, amphetamine, has also been shown to increase DA release at relatively lower doses (1 mgakg, s.c.) 15 and to affect 5-HT release at higher doses (2 mgakg, i.p.). 16 Dexfen¯uramine causes 5-HT release at low doses (0.5±1.0 mgakg, i.p.), however at doses above 1.0 mgakg, this 5-HT secondarily enhances DA release. 17 TTX treatment blocks the release by dexfen¯uramine of 5-HT and, thereby, the release of DA, but does not block the direct release of DA by phentermine (Figure 2) or amphetamine. 14 The fact that tetrodotoxin does not completely block DA release induced by amphetamine or phentermine implies that at least part of the effect is via a carrier-mediated mechanism.
Apparently no previous publication has described the effect of phentermine on neurotransmitter release in vivo, possibly because phentermine is an`old' drug and most studies of its mechanism of action were done before in vivo microdialysis was introduced. 11 It has been suggested, based on indirect evidence, that phentermine elicits its antiobesity effect via catecholaminergic systems, since pimozide, a dopamine receptor blocker, blocked phentermine anorexia in the mouse 2 and 6-hydroxydopamine lesions, which destroy DA and noradrenaline terminals, 18 signi®-cantly antagonized the anorectic effect of phentermine. 3 However, no measurements were made of actual DA or noradrenaline levels, and neither pimozide nor 6-hydroxydopamine is entirely speci®c for DA terminals. Hence this paper presents the ®rst direct evidence of the amphetamine-like properties of phentermine.
Phentermine and fen¯uramine have been combined in the hope of reducing the side effects observed (excitation, sedation) when each compound is given separately. 6 Fen¯uramine is actually a racemic compound. 19 Analysis of the pharmacological and biochemical effects of its two isomers has shown that dexfen¯uramine acts via 5-HT mechanisms and suppresses food intake 8 while l-fen¯uramine, by blocking DA receptors and diminishing DA-mediated neurotransmission, secondarily increases DA release, much as haloperidol, another dopamine receptor antagonist, does. 10 Since, as we now show, phentermine directly enhances DA release and thus the activation of DA receptors, the phentermine and l-fen¯uramine probably do counteract each others' effect on DA transmission. The dopaminergic effect of phentermine might also be expected to produce side-effects similar to those of the prototype dopaminergic anorectic, d-amphetamine.
In earlier studies of brain neurotransmitter release utilizing in vivo microdialysis, it was often necessary to measure not the neurotransmitter itself, but its inactive metabolites, because available assays lacked adequate sensitivity. Now that these assays have improved and the neurotransmitters can be measured, it is apparent that treatments can affect neurotransmitter release without necessarily producing parallel Effect of tetrodotoxin (TTX, a sodium channel blocker, 1 mM) on the release of dopamine (DA) induced by phentermine (2 or 5 mg/kg, i.p). TTX, dissolved in the perfusion medium, was applied through the dialysis probe starting 60 min before (®rst arrow) the administration of phentermine (second arrow), and continuing throughout the experiment. Each point represents the mean of samples collected during the prior 20 min. Data were graphed as means AE S.E.M. n 4±6. *P`0.05; **P`0.01. changes in metabolite levels. 20±23 This probably re¯ects the fact that re-uptake, and not metabolism, is the means whereby such neurotransmitters are inactivated. For this reason, we do not measure levels of DA or 5-HT metabolites in studies on dopaminergic or serotoninergic neurotransmission.
In conclusion, phentermine increases striatal DA release in freely moving rats, and TTX reduces, but does not fully block this effect.
